Equities

Cytokinetics Inc

Cytokinetics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)47.67
  • Today's Change-2.19 / -4.39%
  • Shares traded1.82m
  • 1 Year change+50.19%
  • Beta0.7893
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform12
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 17 analysts offering 12 month price targets for Cytokinetics, Inc. have a median target of 80.00, with a high estimate of 120.00 and a low estimate of 60.00. The median estimate represents a 67.82% increase from the last price of 47.67.
High151.7%120.00
Med67.8%80.00
Low25.9%60.00

Earnings history & estimates in USD

On Nov 06, 2024, Cytokinetics, Inc. reported 3rd quarter 2024 losses of -1.36 per share.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-0.23%
Cytokinetics, Inc. reported annual 2023 losses of -5.45 per share on Feb 27, 2024.
Average growth rate-29.00%
More ▼

Revenue history & estimates in USD

Cytokinetics, Incorporated had 3rd quarter 2024 revenues of 463.00k. This missed the 1.20m consensus estimate of the 15 analysts following the company. This was 89.96% below the prior year's 3rd quarter results.
Average growth rate+77.01%
Cytokinetics, Incorporated had revenues for the full year 2023 of 7.53m. This was 92.04% below the prior year's results.
Average growth rate+19.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.